Medicines Australia Statement on TGA’s provisional approval of AstraZeneca’s COVID-19 vaccine

16 February 2021: Medicines Australia welcomes the TGA’s decision granting provisional approval of the AstraZeneca/Oxford University COVID-19 vaccine, marking the second COVID-19 vaccine to receive regulatory approval in Australia.  

This landmark decision is a testament to the swift action, hard work, and unprecedented collaboration between the industry, Government, and scientific community to address the pandemic.

Initial supply of the vaccine will be imported into Australia from overseas, however ongoing supply will be manufactured locally by CSL making it available for use in Australia throughout the year.

Prior to supply of vaccines manufactured onshore, AstraZeneca will submit further information and data to the TGA to confirm that onshore manufacturing will meet strict quality standards.

Medicines Australia will continue to work closely with all partners across the healthcare ecosystem locally and globally to advance progress in our fight against Covid-19 and ensure Australians have access to necessary vaccines.  

Read the TGA Statement for more.

For further information, please contact